9 results about "Paroxetine" patented technology

Disclosed herein is an anti-tumor pharmaceutical composition based on immune checkpoint blockade and use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride, and a T-cell enhancer, wherein the T-cell enhancer is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, cannabidiol and paroxetine hydrochloride were first found to be capable of effectively reducing the expression of PD-L1 on the tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the ability of T cells to kill tumor cells. The T-cell enhancer added on this basis can further increase the quantity and activity of T cells, significantly increase the killing ability of T cells after immunosuppression is relieved, and greatly improve the anti-tumor effect of the drug. The components of the pharmaceutical composition used in the present invention, namely, cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin, can exert a synergistic effect and improve the anti-tumor effect.

The utility model belongs to the technical field of paroxetine hydrochloride tablet manufacturing, and particularly relates to a structure capable of improving paroxetine hydrochloride tablet wet granulation efficiency, which comprises a granulator body, a control panel is mounted at the top end of the granulator body, a granulation box is connected to the top end of the granulator body and is positioned on one side of the control panel, and the control panel is mounted on the granulation box. The top end of the granulating box is correspondingly connected with a first feeding port and a second feeding port, the bottom end of the outer side wall of the granulating box is connected with a discharging port, the electric push rod is matched with the arc-shaped scraping plate, and the arc-shaped scraping plate can move up and down in the granulating box, so that materials attached to the inner wall of the interior of the granulating box are cleaned; the conditions that the stirring and mixing speed needs to be reduced during manual cleaning, meanwhile, the mixing effect is affected due to the fact that materials are attached to the inner wall of the interior of the granulation box, and stirring and mixing need to be conducted for a longer time are avoided, and then the paroxetine hydrochloride tablet wet granulation efficiency is improved by cleaning the materials attached to the inner wall of the interior of the granulation box.

The present invention relates to an orally disintegrating tablet manufactured by a direct compression method comprising paroxetine or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orally disintegrating tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. The present invention also relates to the process for preparing the said solid pharmaceutical composition.

Disclosed herein is an anti-tumor pharmaceutical composition based on immune checkpoint blockade and use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride, and a T-cell enhancer, wherein the T-cell enhancer is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, cannabidiol and paroxetine hydrochloride were first found to be capable of effectively reducing the expression of PD-L1 on the tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the ability of T cells to kill tumor cells. The T-cell enhancer added on this basis can further increase the quantity and activity of T cells, significantly increase the killing ability of T cells after immunosuppression is relieved, and greatly improve the anti-tumor effect of the drug. The components of the pharmaceutical composition used in the present invention, namely, cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin, can exert a synergistic effect and improve the anti-tumor effect.

A method of treating premature ejaculation in men may include administering a therapeutically effective dosage of a formulation to a patient in need thereof. The formulation for treating male premature ejaculation may include a phosphodiesterase 5 inhibitor (PDE5i), such as Tadalafil; an alpha-1 adrenoreceptor (alpha-1a) selective antagonist, such as Silodosin; and a selective serotonin reuptake inhibitor (SSRI), such as Paroxetine.

Compositions and methods are provided for administering patusutine, or a pharmaceutically acceptable salt thereof, to a patient suffering from a liver injury.

The application discloses a method for simultaneously detecting the concentration of six drugs in blood, comprising the following steps: S1, taking a blood sample, centrifuging, and adding methanol to precipitate protein; S2, preparing a series of concentration calibration solution, quality control sample and internal standard working solution; S3, adding the internal standard working solution to the supernatant 1 prepared in S1, vortex mixing, centrifuging, and taking the supernatant 2; S4, using high performance liquid chromatography-tandem mass spectrometry to detect the supernatant 2 obtained in S3 for the selected drugs, and performing mass spectrometry screening analysis on the basis of the retention time of the compound, two pairs or three pairs of parent ions / daughter ions; the drugs include one, multiple or all of fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram and escitalopram; the detection method provided by the application has the characteristics of simple and convenient sample pretreatment, small required sample volume, high sensitivity, high accuracy and high throughput.

The invention relates to the technical field of neuroscience and drugs, and discloses application of parecoxib as an MEF2A transcription inhibitor in preparation of antiepileptic drugs, which is characterized in that the parecoxib is in targeted combination with N-terminal alpha1 helix and MADS box structural domain of MEF2A protein to inhibit DNA binding capacity of MEF2A, so that downstream NEK7 / CD74 gene transcription is blocked, and microglial cell mediated neuroinflammation is reduced; according to the present invention, the transcriptional activity action mechanism of parecoxib is inhibited through the MEF2A targeting DNA binding interface, specifically, the parecoxib is specifically bound with the N-terminal alpha 1 helix (residues ARG17, THR20, PHE21, LYS23 and ARG24) and MADS box structure domain of MEF2A so as to inhibit the conformational change and the DNA binding ability (the molecular docking simulation shows the high affinity binding), and the transcription of the downstream target gene (such as NEK7 and CD74) is inhibited by blocking the binding of the MEF2A and the DNA so as to inhibit the transcriptional activity of the MEF2A; therefore, the activation of NLRP3 inflammasomes is reduced; excessive activation of microglial cells is inhibited, and the steady state of the neural network is maintained.

The invention discloses application of an Eloralintide and paroxetine combination, a compound preparation and a preparation method, and belongs to the technical field of depression complicated with obesity treatment. Wherein the mass ratio of the Eloralintide to the paroxetine is (1: 10) to (1: 20). The Eloralintide and the paroxil provided by the invention have a synergistic effect, so that the bioavailability is improved, the side effect is reduced, and a new effective treatment choice is provided for obesity caused by depression. Animal experiment results show that after the two are combined, the effects of reducing body weight, improving depression-like behaviors and regulating metabolic functions are obviously better than those of single drug treatment, and the composition has a wide clinical application prospect.